The genetic complexity and heterogeneity of the sporadic forms of Parkinson's disease (PD) are posing a formidable challenge to disentangle their direct molecular causes. To advance this research, we plan to coordinate our local biorepositories of PD biological specimens creating a standardized and integrated national resource. In this framework, we plan to collect more samples from additional sporadic PD cases and to extend the sampling to patients with REM sleep behavior disease. We plan a large campaign of whole genome sequencing including about 200 patients to identify rare genomic variants plausibly associated with these diseases. In addition, we will standardize the generation and quality control of iPSC lines to make available to the scientific community. Finally, we will combine iPSC technology and gene editing to functionally assess the relative impact of rare variants in coding regions inherited together as a polygenic trait previously identified in selected sporadic PD cases
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
motor symptoms of PD and RBD patients will be evaluated with Hoehn and Yahr (HY) score
Timeframe: 2 years
motor and non motor symptoms of PD and RBD patients will be evaluated with MDS-UPDRS
Timeframe: 2 years
clinical evaluation of of sleep disorders in PD and RBD patients
Timeframe: 2 years
clinical evaluation of of sleep disorders in PD and RBD patients by Polysomnography
Timeframe: 2 years
clinical evaluation of cognitive impairment of PD and RBD patients by MoCA test score
Timeframe: 2 years
clinical evaluation of levodopa-induced dyskinesia (LID) in PD patients
Timeframe: 2 years
identification of variants/mutations
Timeframe: 2 years
association with phenotypic manifestation of PD
Timeframe: 2 years